Chengdu Zhifei Biological Products: Application for production registration of 15-valent pneumococcal conjugate vaccine accepted.

Chia Tai Biotech announced that its wholly-owned subsidiary, Chia Tai Green Bamboo, has received a "Notice of Acceptance" issued by the National Medical Products Administration for the production registration of a 15-valent pneumococcal conjugate vaccine developed by Chia Tai Green Bamboo. This vaccine is a preventive biological product that covers the 15 serotypes with the highest detection rates in the Asian region, and is used to prevent diseases caused by related serotypes of pneumococcus. As of the disclosure date of the announcement, there are no other 15-valent pneumococcal conjugate vaccines approved for market. The acceptance of the production registration application for the 15-valent pneumococcal conjugate vaccine aligns with the company's research direction of developing multi-valent vaccines. If the project progresses smoothly, it will synergize with the company's already marketed 23-valent pneumococcal polysaccharide vaccine and the 26-valent pneumococcal conjugate vaccine currently in Phase I/II clinical trials, further solidifying the company's pneumonia vaccine matrix, strengthening the company's market position, and enhancing its competitiveness.